<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745898</url>
  </required_header>
  <id_info>
    <org_study_id>U24HL140412-01_UG3</org_study_id>
    <secondary_id>U24HL140412-01</secondary_id>
    <nct_id>NCT03745898</nct_id>
  </id_info>
  <brief_title>The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea</brief_title>
  <official_title>The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea (LOFT-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the long-term effects of Nocturnal Oxygen Therapy
      (NOXT) on the mortality and morbidity of patients with stable heart failure and a reduced
      ejection fraction (HFrEF), already receiving optimal guideline-directed medical therapy
      (GDMT), who have central sleep apnea (CSA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First occurrence of mortality due to any cause or an unplanned hospitalization for worsening heart failure or a life-saving cardiovascular (CV) intervention</measure>
    <time_frame>Through study completion, an average of 2.5 years</time_frame>
    <description>This is a composite primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent event analyses of morbidity</measure>
    <time_frame>Through study completion, an average of 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent event analyses of mortality</measure>
    <time_frame>Through study completion, an average of 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity</measure>
    <time_frame>12 months</time_frame>
    <description>Exercise capacity will be assessed by the change in 6-minute hall walk distance (6MHWD) test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Symptoms - HF disease-specific quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>HF disease-specific quality of life will be assessed by the change in the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life for those who have heart failure. An overall summary score is derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Symptoms - Generic-quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Generic-quality of life will be assessed by the change in the Euroqol - 5 Dimensions (EQ-5D) questionnaire. The questionnaire comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. There is no total score or range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Symptoms - Depressive symptoms</measure>
    <time_frame>12 months</time_frame>
    <description>Depressive symptoms will be assessed by the change in the Patient Health Questionnaire - 8 items (PHQ-8). A scores ranges from 0 to 24. A score greater than 10 is considered major depression and a score 20 or more is considered severe major depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life and Symptoms - Sleep symptoms and sleep related daytime impairment</measure>
    <time_frame>12 months</time_frame>
    <description>Sleep symptoms and sleep related daytime impairment will be assessed by the change in the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance and Sleep Related Impairment Questionnaires. Scores range from 8 - 40. The final score is represented by the T-score, a standardized score with a mean of 50 and a standard deviation (SD) of 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>12 months</time_frame>
    <description>Functional status will be assessed by the change in New York Heart Association (NYHA) Functional Class Ranking</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">858</enrollment>
  <condition>Heart Failure</condition>
  <condition>Central Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Nocturnal Oxygen Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active nocturnal oxygen therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Nocturnal Oxygen Therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham nocturnal oxygen therapy (room air)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Active nocturnal oxygen concentrator</description>
    <arm_group_label>Nocturnal Oxygen Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Room Air</intervention_name>
    <description>Sham nocturnal oxygen concentrator (room air)</description>
    <arm_group_label>Sham Nocturnal Oxygen Therapy</arm_group_label>
    <other_name>Sham Oxygen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 21 years at the date of consent.

          -  History of chronic, stable heart failure with reduced ejection fraction with left
             ventricular ejection fraction (LVEF) ≤ 45% determined by echocardiography,
             radionuclide angiography, left ventriculography, or cardiac magnetic resonance
             imaging, within the year prior to enrollment.

          -  Central sleep apnea, defined using as an apnea-hypopnea index (AHI) &gt; 15/h with ≥ 50%
             central events (apnea and hypopneas).

          -  New York Heart Association (NYHA) Class III or IV, or NYHA Class II with ≥ 1
             hospitalization for HF in the last 24 months.

          -  Treatment with stable, optimized guideline-directed medical therapies (GDMT) according
             to applicable guidelines in the U.S. and Canada, where stable is defined as the
             addition of no new class of disease-modifying drug for ≥ 30 days prior to
             randomization.

          -  In the investigator's opinion, willing and able to comply with all study requirements

          -  Able to fully understand study information and sign an Institutional Review Board
             (IRB) approved informed consent

        Exclusion Criteria:

          -  Current positive airway pressure use of diagnosis of Obstructive Sleep Apnea (OSA).

          -  Oxygen saturation &lt; 90% at rest during the day.

          -  Oxygen saturation &lt; 88% for &gt; 5 continuous minutes during sleep unaccompanied by
             respiratory events.

          -  Chronic daytime or nighttime use of supplemental oxygen.

          -  Current smoker or bed partner that smokes in the bedroom.

          -  Severe pulmonary disease requiring continuous home oxygen therapy or the continuous or
             frequent intermittent use of oral steroids or documented severe chronic obstructive
             pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) &lt; 50%.

          -  Cardiac surgery, percutaneous coronary intervention, myocardial infarction or unstable
             angina within the previous 3 months.

          -  Transient ischemic attack or stroke within the previous 3 months.

          -  Cardiac resynchronization therapy implantation scheduled or performed within 3 months
             prior to randomization.

          -  Primary hemodynamically-significant uncorrected valvular heart disease (obstructive or
             regurgitant) or any valvular disease expected to require surgery during the trial

          -  Acute myocarditis/pericarditis or other cause of potentially reversible cardiomyopathy
             (e.g., post-partum cardiomyopathy, tachycardia-induced cardiomyopathy), within the
             previous 6 months.

          -  End-stage (Stage D) heart failure (HF) requiring continuous outpatient intravenous
             (IV) inotropic therapy, placement of ventricular assist device, listing for cardiac
             transplantation, or end-of-life care (e.g. hospice care).

          -  Pregnancy or of child bearing potential without a negative pregnancy test within 10
             days prior to enrollment.

          -  Life expectancy &lt; 1 year for diseases unrelated to chronic HF.

          -  Enrolled or planning to enroll in another study that may conflict with protocol
             requirements or confound subject results in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emily Kaplan</last_name>
    <phone>617-278-0382</phone>
    <email>ekaplan1@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michelle Reid, MPH</last_name>
    <email>mlreid@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trina Hughes</last_name>
      <phone>520-626-9372</phone>
      <email>trina@deptofmed.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Flores</last_name>
      <phone>860-877-0071</phone>
      <email>adam.flores@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Barletta</last_name>
      <phone>305-243-2568</phone>
      <email>Pxb450@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Moroni</last_name>
      <phone>312-503-0018</phone>
      <email>francesca.moroni@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Eikeland</last_name>
      <phone>773-834-5797</phone>
      <email>linda.eikeland@uchospitals.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Health System</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Haffey</last_name>
      <phone>816-932-2680</phone>
      <email>khaffey@saint-lukes.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Sheehan</last_name>
      <phone>617-732-6237</phone>
      <email>msheehan1@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilanda Gabriel</last_name>
      <phone>617-975-7637</phone>
      <email>wgabriel@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Huang</last_name>
      <phone>313-745-9224</phone>
      <email>hhuang@dmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Stilinovic</last_name>
      <phone>314-747-2246</phone>
      <email>sstilinovic@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prince Thomas</last_name>
      <phone>505-272-6511</phone>
      <email>prthomas@salud.unm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samira Khan</last_name>
      <phone>212-241-6898</phone>
      <email>samira.khan@mssm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandria Davis</last_name>
      <phone>513-558-2187</phone>
      <email>Davis5ax@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MetroHeath Systems</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Cook</last_name>
      <phone>216-778-7373</phone>
      <email>dcook@metrohealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Aylor</last_name>
      <phone>216-445-1698</phone>
      <email>aylorj@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brougher</last_name>
      <phone>614-292-3962</phone>
      <email>sarah.brougher@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Highland Hills</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justina Vigluicci</last_name>
      <phone>216-844-2897</phone>
      <email>Justina.vigluicci@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Launchbury</last_name>
      <phone>503-418-1722</phone>
      <email>nadeauk@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Vincent</last_name>
      <phone>412-383-3556</phone>
      <email>vincentgm@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Main Line Hospitals</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ebuwu Erebor</last_name>
      <phone>484-476-2756</phone>
      <email>erebore@mlhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Rangel</last_name>
      <phone>713-500-6851</phone>
      <email>Mary.Rangel@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Penn</last_name>
      <phone>801-585-2469</phone>
      <email>brittany.penn@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Curtin</last_name>
      <phone>206-616-6432</phone>
      <email>lcurtin@cardiology.washington.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Peterson</last_name>
      <phone>608-256-1901</phone>
      <phone_ext>11902</phone_ext>
      <email>apeterson@wisc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>June 6, 2020</last_update_submitted>
  <last_update_submitted_qc>June 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Susan Redline</investigator_full_name>
    <investigator_title>Professor and Senior Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Central</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All relevant deidentified data will be deposited in Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) and the National Sleep Research Resource (NSRR)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

